AbbVie Stock: JPMorgan Backs $11B Apogee Therapeutics Deal
22 Jun 2026 · 09:15 UTC · CoinCentral RSS Feed · Original source
Read original at CoinCentral RSS Feed →
Summary
AbbVie is nearing a $10.9 billion all-cash deal to acquire Apogee Therapeutics. The offer represents a 60% premium to Apogee's recent closing price. JPMorgan has reiterated a Buy on AbbVie, suggesting the deal is a strategic fit.
Why it matters
This acquisition news pertains to AbbVie and its strategic move in the pharmaceutical industry. While it may influence stock markets, its relevance to cryptocurrency markets is minimal. The low credibility score of the source further indicates that this news may not be reliable or impactful.
Expected impact
The news of AbbVie's acquisition of Apogee Therapeutics is unlikely to have any significant impact on the cryptocurrency markets. The deal is primarily focused on the pharmaceutical sector and does not directly relate to cryptocurrencies or blockchain technology.